Purmorphamine 

Purmorphamine (GMP) is Purmorphamine (HY-15108) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Purmorphamine is a smoothened/Smo receptor agonist with an EC₅₀ of 1 μM^[1].

Purmorphamine (GMP) (1.5 μM, 1 week) can generate embryoid bodies (EBs) from human iPS cells (hiPS2) and hESCs (HSF1)^[1].
Purmorphamine (GMP) (1.5 μM) converts hPSCs to NKX2-1 positive MGE cells^[2].
Purmorphamine (GMP) (2 μM, day 28-35) promotes ventralization of the brain spheroids in differentiation process from hiPSCs^[3].
Purmorphamine (GMP) (1 μM) together with retinoic acid (RA, 2 μM) promotes hiPSC differentiation into functional neural tissue, indicated by the expression of neuronal marker β-tubulin III (βT-III)^[4].
Purmorphamine (GMP) (day5-7) induces hESCs differentiation into dopaminergic (DA) neurons^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

520.62

C₃₁H₃₂N₆O₂

483367-10-8

N1(C2=CC=C(NC3=NC(OC4=CC=CC5=C4C=CC=C5)=NC6=C3N=CN6C7CCCCC7)C=C2)CCOCC1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Karumbayaram S, et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells. 2009 Apr;27(4):806-11.  [Content Brief]

  [2]. Hu Y, et al. Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. J Neurosci Methods. 2016 Jun 15;266:42-9.  [Content Brief]

  [3]. Hua T, et al. Phenotypic, metabolic, and biogenesis properties of human stem cell-derived cerebellar spheroids. Sci Rep. 2022 Jul 27;12(1):12880.  [Content Brief]

  [4]. Sharma R, et al. 3D Bioprinting Pluripotent Stem Cell Derived Neural Tissues Using a Novel Fibrin Bioink Containing Drug Releasing Microspheres. Front Bioeng Biotechnol. 2020 Feb 11;8:57.  [Content Brief]

  [5]. Sundberg M, et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013 Aug;31(8):1548-62.  [Content Brief]